INTRODUCTION
The development of an effective vaccine remains a key challenge of HIV-1 research. Multiple groups have undertaken knowledge-based approaches with the aim of developing an effective B-cell-based vaccine. These approaches seek information on two critical areas: broadly neutralizing antibodies (bNAbs), which develop after 5þ years in a substantial proportion of patients infected by HIV-1 and are capable of neutralizing diverse strains of HIV-1 [1-5,6 && ,7 && ]; and the structure and conformations of the HIV-1 envelope (Env), a trimeric heterodimer comprising three gp120-exterior subunits and three gp41-transmembrane subunits, which is the sole target of virus-directed bNAbs (reviewed in [8 & ,9] [15, 16] are revealing structural features of the HIV-1 Env, a type 1 fusion machine that uses conformational change to drive fusion of viral and cellular membranes. These studies provide the context in which to situate bNAb sites of vulnerability. Meanwhile, insights from antibody-virus coevolution PGT141-145/PGDM1400-1412 and CAP256-VRC26.01-33) [17, [39] [40] [41] 43, 44 && , 45 ,47] recognize a quaternary epitope formed at the trimer apex involving V1V2 and N-linked glycans at positions 156 and 160. bNAbs in this group are generally trimer-specific, bind with a stoichiometry of one antibody per Env trimer and utilize a protruding CDR H3 (>24 residues, as defined by Kabat et al. [81] ) to penetrate the dense N-linked glycosylation covering most of the Env-protein surface. The rarity of recombination events that generate suitable CDR H3s has limited the vaccine implications of apex binders; a recent report of a new apex-targeting antibody, N123-VRC38.01, identifies a side chain mechanism of recognition that allows for a shorter CDR H3 [48] .
Glycan-V3-directed bNAbs (e.g. PGT121, PGT128 and PGT135 classes; PGDM11-14, PGDM21 and PCDN antibodies; BG18 and DH270 lineages) [ ] utilize moderately long CDR H3 loops and varying angles of approach to recognize a 'supersite of vulnerability' [54] centered on a high-mannose patch near N332. Recognition by these antibodies often includes a GDIRpeptide motif at the base of V3, which has been implicated in binding by the CCR5 coreceptor [55 & ]. CD4-binding site (CD4bs)-directed bNAbs bind to a functionally conserved, recessed region on gp120 hidden amongst glycans, thereby requiring a restricted approach angle to achieve potency and breadth [59] . CD4bs bNAbs can be classified as either VH-gene restricted (e.g. antibodies VRC01, 8ANC131 or IOMA) [14
&&
, 38, 60, 61, 84] or CDR H3 loop-dominant (e.g. antibodies HJ16 or CH103) [58, 59, 85] . VRC01-class bNAbs use CD4 mimicry to achieve remarkable breadth, with select antibodies, such as VRC01, able to neutralize over 90% of HIV-1 and the recently identified N6 antibody able to neutralize 98% of HIV-1 isolates [62 && ]. bNAbs targeting the gp120-gp41 interface (e.g. antibodies 35O22, PGT151, 8ANC195, 3BC315/ 3BC176 and CAP248-2B) [63,65,67,69,72 & ] represent the newest bNAb category; the epitopes for these antibodies, although not always overlapping, are primarily trimer-specific, span regions in both gp120 and gp41 and generally include glycan. Antibody 8ANC195, however, can also bind to gp120 monomers and recognizes different conformational states of prefusion trimer [68] Vaccine developers are uncertain as to how much of the antibody-developmental pathway vaccine immunogens should mimic to elicit a target antibody lineage, with some attempting to simulate the antibodyEnv coevolution process and others focusing on only the recognized epitope.
An additional layer of complexity involves the appropriate conformation of the HIV-1 Env that should be used to situate the target site of vulnerability for vaccine elicitation. 
STRUCTURES AND ENTRY MECHANISM OF HIV-1 ENVELOPE
In addition to the overall prefusion to postfusion transition that all type 1 fusion machines undergo to drive viral-cellular membrane fusion, HIV-1 Env uses additional conformations, such as the prefusion-closed state, to hide from the humoral immune system, or CD4-bound or postfusion states, which contain few neutralizing epitopes, to mislead the humoral immune response (Fig. 1) . Thus, although an antibody such as VRC01 may bind to diverse Env conformations and states, only a specific Env conformation may allow for the elicitation of VRC01-like bNAbs. Investigations of other type 1 fusion machines are demonstrating the importance of immunizing with the appropriate conformation, with prefusion conformation of the fusion glycoprotein of respiratory syncytial virus eliciting manyfold higher titers than the postfusion conformation [91] [92] [93] [94] [95] . With HIV-1, the importance of Env conformation in vaccine immunogens has been demonstrated by the elicitation of autologous neutralizing antibodies against tier-2 neutralizationresistant isolates by Env trimers stabilized in the prefusion-closed state [96] [97] [98] .
Studies using smFRET [10, 99] reveal that in addition to the prefusion-closed state, HIV-1 Env transitions through a high-FRET state characterized by a single-bound CD4 and an intermediate form that binds to multiple CD4s. Furthermore, negativestain electron microscopy (EM) studies suggest that prefusion Env trimers of different strains can 'breathe' or exist in partially open conformations that allow recognition by antibodies like b12, which cannot readily bind the fully closed prefusion conformation [100] . In all prefusion forms, gp41 interactions remain largely intact, whereas gp120 subunits undergo varying degrees of movement upon CD4 binding. Recent studies suggest that a ) and postfusion gp120 and gp41 states (gp120 based on PDB ID 3JWD [88] , 3U2S [41] and 2B4C [89] ; gp41 based on PDB ID 2EZO [90] ) are colored by bNAb epitope with gp120 shown in light gray, gp41 in dark gray and glycans depicted as gray sticks. Representative members within each bNAb category are listed according to the conformational envelope state they recognize. Nonneutralizing antibodies [e.g. A32, C11 (gp120 C1 region), F105, b13 (CD4-binding site), 13H11 (gp41) and gp41-directed Cluster I and II Abs] bind to states other than the prefusion-closed trimer and are not listed. Throughout the HIV-1 entry mechanism, gp41 adopts at least three different conformations, including the prefusion state, an extended prehairpin intermediate and a postfusion six-helix bundle. Structural details of gp41 conformational rearrangement following CD4 and coreceptor binding are not as well characterized at the atomic level. The prehairpin intermediate, defined by extension of the gp41 fusion peptide into the target cell membrane and a fully assembled HR1 helix, is a target for peptide and small molecule inhibitors but can also be recognized by neutralizing antibodies like D5 [106] . The postfusion Env state, comprising the gp41 six-helix bundle [107] [108] [109] , shed gp120 and receptor-bound gp120 monomer, exposes immunodominant epitopes leading to a nonneutralizing antibody response [110] . Situating sites of vulnerability into the Env conformation most appropriate for vaccine elicitation may be critical for structure-based immunogen design.
VACCINE DESIGN INCORPORATING BROADLY NEUTRALIZING ANTIBODY INSIGHTS AND ENVELOPE CONFORMATION
Structural information on antibody/epitope complexes and information on the B-cell development (B-cell ontogeny) and lineage-based coevolution of virus and antibodies have led to strategies for vaccine design that could be applied for each site of vulnerability separately and/or synergistically (Fig. 2) .
Structure of the epitope
Structural information on the bNAbs bound to their epitope has been crucial for understanding the sites targeted on HIV-1 Env and their epitopes. These structures provide the basis for immunogen design based on recognized epitope (Fig. 2) . Structures of apex V1V2-directed antibodies (PG9, PG16 [41, 42] and more recently CH03 [44 && ]) in complex with V1V2 domain scaffolds have been used as templates for glycosylated V1V2 peptide [111] and V1V2-epitope scaffold immunogens [112,113 & ]. Structures of N332 glycan patch-directed antibodies (PGT128, PGT135 and PGT122 [51, 53, 54] ) with gp120 core or HIV-1 Env trimer have highlighted a supersite of vulnerability that can be targeted from different angles and have led to designs of V3 glycosylated peptides [115 & ] and V3 epitope scaffolds [112] . Efforts have also been pursued to design scaffolds for the CD4bs-directed bNAb b12, based on its structure in complex with gp120 core [117] . Other designs have focused on the VRC01-epitope [118, 119] . The recent discovery of antibodies targeting the fusion peptide of the HIV-1 Env trimer has also led to the designs of immunogens that present the fusion peptide [70 && ,121]. Finally, designs of epitope scaffolds and peptides of the MPER have been sought as soon as structures became available [122] [123] [124] [125] [126] [127] [128] [129] . Although some of the scaffold-elicited antibodies recognize the epitope in a similar manner as the MPER bNAbs, none were able to broadly neutralize multiple strains of HIV. More recently, the design of a soluble mimic of the HIV-1 Env trimer allowed presentation of multiple bNAb epitopes. These SOSIP immunogens have been shown to induce reproducible autologous neutralization in animal models [96] .
B-cell ontogeny
Select bNAbs can arise in multiple HIV-1-infected donors and share common features such as gene usage and mode of recognition [61] . This led to the concept that immunogens can be designed to induce the development of specific classes of bNAbs. Ontogeny-based strategies include structural information of antibody maturation from germline to mature bNAb to guide design of germline-targeting and intermediate immunogens to elicit bNAbs by vaccination (Fig. 2) . The most characterized is the VRC01 class of bNAbs, which have been isolated from multiple HIV-1-infected donors, use VH1-2 Ã 02, have a CDR L3 of five amino acids and structurally recognize the CD4bs with CDR H2 contacts encoded by the VH1-2 Ã 02 gene [60, 61, 131] . Efforts have been made to induce these specific antibodies by using engineered gp120 proteins, notably eOD and 426c, that show binding to the germline versions of these bNAbs [26 ability of the eOD-GT8 60mer to induce the maturation of appropriate germline [20 && ]. Although potentially promising, the high degree of somatic hypermutation needed to achieve neutralization within the VRC01-class suggests that immunization may require years of maturation [23] . Also potentially confounding is the recent identification of related antibodies, such as IOMA or N6, which achieve neutralization breadth and potency by following alternative maturation pathways [14 && ,62 && ]. Other efforts have also been pursued to design immunogens that will bind the germline version of the V1V2-directed bNAbs at the apex of the trimer as some of these bNAbs isolated from different individuals also share common elements [44 && ,114] . Overall, the general applicability of ontogeny-based strategies is still being determined. Should these strategies be confined to reproducible lineages? Despite no evidence of PGT121-class antibodies appearing in other donors, efforts have also been made to develop immunogens that bind developmental intermediates of this family and to elicit PGT121-like antibodies in knock-in mice [27 && ,116 && ]. Similarly, despite MPER-directed antibodies all utilizing different modes of binding, the 10E8 developmental pathway may still be useful as a vaccine template [130 & ]. A key issue may be determining the critical 'difficult' or 'rate-determining' step in the B-cell ontogeny. If immunization were to ease that rate-determining step [such as the initial binding of antigen to the UCA (unmutated common ancestor) for the VRC01-class], then it should be helpful in re-elicitation. However, if the difficult/ rate-determining step involved the creation of a FIGURE 2. Structure-based approaches to vaccine design as guided by broadly neutralizing antibodies. Structural information of the broadly neutralizing antibodies in complex with their epitopes can serve to guide vaccine design approaches that include epitope scaffolds, domain scaffolds, stabilized trimers and immunogens targeted to select steps in template B-cell ontogenies.
particular CDR H3/recombination that led to the lineage (as may be the case with the 10E8 and PGT121 lineages), then immunizing with UCA of intermediate-binding antigens may not be helpful in wild-type settings.
Coevolution
With the advance of NGS technologies, it is now possible to follow the coevolution of virus and bNAb lineages during HIV-1 infection. These efforts have led to a better understanding of the viral antigens that drive bNAb development. They have also led to the concept of replicating the longitudinal viral milieu that generated bNAbs to induce their 'reelicitation' [132] . 
CURRENT BEST: VACCINE-ELICITED SERA AND ANTIBODIES
Over 30 years after the discovery of HIV, no vaccine exists despite substantial efforts to design immunogens based on HIV-1 Env, the sole target of virusdirected neutralizing antibodies (reviewed in [8 & ]). Nonetheless, the last few years have seen enormous progress in the quality of the immune response elicited by a new generation of immunogens (described above) through vaccination in different animal models (Table 2) .
Wild-type animal models
Immunizations with soluble near-native mimics of the HIV-1 viral spike as immunogens, such as certain VLPs and SOSIP trimers, have elicited high titers of autologous tier-2 neutralization (ID 50 in the 100-1000 range) [96, 133] Current best autologous and heterologous tier-2 neutralization in different animal models using various immunogens obtained by structure-based design. Env, envelope; T/F, transmitted/founder.
strategies (reviewed in [137
, to go from elicitation of autologous neutralizing antibodies to elicitation of bNAbs. However, no reports through 2016 achieve serum neutralization in wild-type animals with even moderate breadth (e.g. 10-20%) against tier-2 isolates.
Germline knock-in mice
To incorporate B-cell ontogeny information and to better mimic the human immune response, various germline knock-in animal models have been developed. Sequential immunization of VH1-2 Ã 02-rearranging mice (which also expressed a VRC01-antibody precursor light chain, with gp120 proteins designed to engage VRC01 germline and intermediate antibodies) led to elicitation of weak autologous tier-2 neutralization [29 && ]. Similarly, careful consideration of prime/boost strategy, using specific immunogens designed for priming (eOD) and for boosting the functional maturation of the previously primed VRC01-class precursors (GT3 and SOSIP N276D), has led to weak neutralization of autologous tier-2 virus in a VRC01 germline heavy-chain knock-in mouse model [28 && ]. Also notable has been the heterologous tier-2 HIV-1 neutralization achieved by sera and antibodies from germline knock-in mice containing the inferred germline heavy chain and the predicted germline light chain of antibody PGT121 immunized with specifically engineered antigens designed to bind germline PGT121 antibody and intermediate [27 && ,116 && ]; although potentially exciting, the prevalence of appropriate germline rearrangements that can bind to the engineered immunogens in wild-type setting remains unclear.
Mutated knock-in mice
To compare the requirements for neutralization, mutated knock-in mice versions have also been engineered, in which the human heavy chain is fully mutated but is paired with a mouse germline light chain, thus producing a synthetic intermediate antibody [25, 27 && ]. Immunization with native-like Env trimers, such as SOSIP, elicited heterologous neutralization of tier-2 viruses in human 3BNC60 IgH knock-in mice [25] .
Heterologous tier-2 neutralization was also observed in the knock-in mice containing the fully mature heavy chain of PGT121 and the predicted germline light chain [27 && ]. Although the reproducibility of the heterologous tier-2 neutralization of the sera of immunized animals appeared higher than in the corresponding germline knock-in model, antibody neutralization was not improved compared with the germline knock-in model [27 && ].
Overall, it is unclear how the described animal experiments will translate into humans; nevertheless, they suggest that sequential immunizations with specifically designed immunogens, as guided by structure and bNAb lineage, may be a feasible vaccination strategy for elicitation of bNAbs.
CONCLUSION
Hundreds of bNAbs against HIV-1 have been identified over the last 5 years. Information on the sites on Env and the conformations of Env that these bNAbs recognize -along with the B-cell ontogenies by which these antibodies arise and the viral coevolution that stimulated their development -is revolutionizing HIV-1-vaccine design. The impact of this revolution is now winding its way through various models of immunization. Because antibody lineage development is often 'human specific', for example dependent on specific human Ig-germline genes, various knock-in mice have been utilized to evaluate immunogens and to gain insight into bNAb induction by vaccination.
To harness both B-cell ontogeny and viral coevolution information, it may be critical to address two specific questions: first, Env conformation -which conformation of Env optimally presents a target bNAb epitope for vaccine induction? Often bNAbs recognize multiple conformational states. In wild-type settings, when 'off-track' sublineages and 'off-target' immunodominant antibodies may compete for antigen, the optimal conformation of the Env immunogen may be critical for elicitation. Second, B-cell lineage -what is the critical 'rate-determining' step? There are many steps in B-cell development. It is important to make sure that the vaccine strategy accelerates the critical rate-determining step (or steps).
In summary, information on bNAbs is guiding HIV-1-vaccine development. Recent structural insights from the HIV-1 entry mechanism have revealed diverse conformations of Env involved in HIV-1 entry. We note that NGS-derived coevolution and B-cell ontogeny information often do not delineate an optimal Env conformation for vaccine elicitation. We highlight the vaccine importance of utilizing the conformation of Env that optimally presents the target bNAb epitope. Cryo-electron microscopy (cryo-EM) structures of a native Env trimer, lacking only the cytoplasmic tail and stabilized by PGT151 or PGT151 and 10E8, provide new details into wild-type Env structure and the PGT151 epitope, which includes the gp41 fusion peptide.
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